Evidence map›Paper›PMID 33657146›Full record

ArticlePloS one2021

AB569, a non-toxic combination of acidified nitrite and EDTA, is effective at killing the notorious Iraq/Afghanistan combat wound pathogens, multi-drug resistant Acinetobacter baumannii and Acinetobacter spp.

Amy L Bogue, Warunya Panmanee, Cameron T McDaniel, Joel E Mortensen, Edwin Kamau, Luis A Actis, Jay A Johannigman, Michael J Schurr, Latha Satish, Nalinikanth Kotagiri and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Amy L BogueDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.
Warunya PanmaneeDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.
Cameron T McDanielDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.
Joel E MortensenDiagnostic Infectious Disease Testing Laboratory and Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
Edwin KamauWalter Reed National Military Medical Center (WRNMMC), Bethesda, MD, United States of America.
Luis A ActisDepartment of Microbiology, Miami University, Oxford, OH, United States of America.
Jay A JohannigmanU.S. Army Institute of Surgical Research, San Antonio, TX, United States of America.
Michael J SchurrDepartment of Immunology and Microbiology, University of Colorado Anschutz School of Medicine, Denver, CO, United States of America.
Latha SatishDepartment of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.
Nalinikanth KotagiriResearch Department, Shriners Hospitals for Children- Cincinnati, Cincinnati, OH, United States of America.ORCID 0000-0003-0066-4563
Daniel J HassettDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.ORCID 0000-0003-2300-4955
University of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · USMiami University · USShriners Hospitals for Children - Cincinnati · USUnited States Army Institute of Surgical Research · USWalter Reed National Military Medical Center · USWright-Patterson Air Force Base · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multi-drug resistant (MDR) Acinetobacter baumannii (Ab) and Acinetobacter spp. present monumental global health challenges. These organisms represent model Gram-negative pathogens with known antibiotic resistance and biofilm-forming properties. Herein, a novel, nontoxic biocide, AB569, consisting of acidified nitrite (A-NO2-) and ethylenediaminetetraacetic acid (EDTA), demonstrated bactericidal activity against all Ab and Acinetobacter spp. strains, respectively. Average fractional inhibitory concentrations (FICs) of 0.25 mM EDTA plus 4 mM A-NO2- were observed across several clinical reference and multiple combat wound isolates from the Iraq/Afghanistan wars. Importantly, toxicity testing on human dermal fibroblasts (HDFa) revealed an upper toxicity limit of 3 mM EDTA plus 64 mM A-NO2-, and thus are in the therapeutic range for effective Ab and Acinetobacter spp. treatment. Following treatment of Ab strain ATCC 19606 with AB569, quantitative PCR analysis of selected genes products to be responsive to AB569 revealed up-regulation of iron regulated genes involved in siderophore production, siderophore biosynthesis non-ribosomal peptide synthetase module (SBNRPSM), and siderophore biosynthesis protein monooxygenase (SBPM) when compared to untreated organisms. Taken together, treating Ab infections with AB569 at inhibitory concentrations reveals the potential clinical application of preventing Ab from gaining an early growth advantage during infection followed by extensive bactericidal activity upon subsequent exposures.

Indexed as

Afghan Campaign 2001-Iraq War, 2003-2011Acinetobacter baumanniiAcinetobacter InfectionsAdultAfghanistanAnti-Bacterial AgentsBiofilmsCells, CulturedDisinfectantsDrug CombinationsDrug Resistance, Multiple, BacterialEdetic AcidFibroblastsGene ExpressionHumansAB569Anti-Bacterial AgentsDisinfectantsDrug CombinationsEdetic AcidNitrites

Identifiers

PMID33657146
PMCPMC7928478
OpenAlexW3135110756

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.